Senior Research Executives from Boehringer Ingelheim and The Garvan Institute to Present at Pharmaxis Investor Research Briefing
Release Date: 15/11/2018 8:30am
Pharmaceutical research company Pharmaxis (ASX: PXS) advises that it will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT) that will feature presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event will also provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.
This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute.
Attendance at this event is by invitation only. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.
Categories: News and Media